Finance

Lists
KYKOF:OTCMKTS
Kyowa Kirin Co Ltd
$15.80
0.00%
(0.00) 1D
Sep 2, 9:30:01 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYKOF...
Mkt. cap
1.26T
Avg. vol.
3.00
Volume
0.00
52-wk high
$18.00
52-wk low
$12.42
Beta
0.48
Shares outstanding
525.64M
No. of employees
5K
Mkt. cap
1.26T
Avg. vol.
3.00
Volume
0.00
52-wk high
$18.00
52-wk low
$12.42
Beta
0.48
Shares outstanding
525.64M
No. of employees
5K
Profile
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Wikipedia
About Kyowa Kirin Co Ltd
CEOMasashi Miyamoto
Employees5.16K
FoundedJul 1, 1949
Headquarters-
SectorPharmaceutical industry
Websitekyowakirin.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
118.80B
147.38B
118.47B
145.16B
Cost of goods sold
28.20B
37.87B
30.22B
36.13B
Cost of revenue
28.20B
37.87B
30.22B
36.13B
Research and development expenses
24.33B
24.35B
27.16B
19.16B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
38.72B
31.35B
41.07B
43.74B
Operating expense
63.05B
72.15B
71.01B
94.49B
Total operating expenses
91.25B
110.02B
101.23B
130.62B
Operating income
27.55B
37.35B
17.23B
14.55B
Other non operating income
-1.69B
13.50B
-7.71B
7.71B
EBT including unusual items
25.95B
39.30B
13.93B
23.54B
EBT excluding unusual items
25.95B
51.23B
13.93B
23.54B
Income tax expense
9.67B
4.86B
1.89B
4.96B
Effective tax rate
37.26%
12.36%
13.59%
21.05%
Other operating expenses
-
3.92B
-
28.59B
Net income
16.28B
34.44B
12.03B
18.58B
Net profit margin
13.70%
23.37%
10.16%
12.80%
Earnings per share
-
-
-
-
Interest and investment income
1.18B
2.71B
5.68B
1.58B
Interest expense
-529.00M
-28.00M
-2.27B
-
Net interest expenses
653.00M
2.68B
3.41B
1.58B
Depreciation and amortization charges
-
12.54B
-
-2.78B
EBITDA
33.97B
44.74B
24.88B
22.32B
Gain or loss from assets sale
-
2.77B
-
5.56B
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps